Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3
Awakn Life Sciences Files Patent Application For A New Class Of Entactogen-Like Molecules To Treat
Universal Ibogaine Enters Drug Supply Agreement Calgary, AB – January 26, 2022 – Universal Ibogaine
Awakn Life Sciences Signs MOU With MAPS Agreement to explore a partnership for MDMA-Assisted Therapy
Sydney Researchers Awarded Over $2.2 Million By Australian Government To Study MDMA, Psilocybin University of
Filament Health and Cybin Therapeutics Announce Licensing Agreement Filament will license PEX010, its proprietary botanical
Universal Ibogaine Announces World-class Clinical Trial Partners In Advance Of Clinical Trial Application For Ibogaine
Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder Novamind (NM) is hosting a
After his brother overdosed in 2019, Timothy Ko founded Entheon Biomedical (ENBI) on his quest
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC MindMed (MNMD) developed a non-hallucinogenic molecule
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead
Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs Entheon Biomedical (ENBI) has begun
Psilocybin Can Reduce Cravings In Alcohol Dependent Rats, And Now We Know Why A study
Psychedelics Use Associated With 55 Percent Decrease In Daily Opioid Consumption, Study Finds A new
Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
Awakn Life Sciences Announces The Findings From Phase II A/B Study Are To Be Published
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder
Clearmind Signs Development and Supply Agreement to Produce its Drug Candidate MEAI Psychedelic Molecule With
